Mouse models for breast cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed.

1. Prevalence of MMTV-like sequences in breast cancer samples in Romanian patients-there is a geographic difference compared to the Western world.Infectious agents and cancer · 2023
   Article
2. Preclinical Models to Study Obesity and Breast Cancer in Females: Considerations, Caveats, and Tools.Journal of mammary gland biology and neoplasia · 2020
   Review
3. The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis.Clinical epigenetics · 2016
   Article
4. Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy.Future oncology (London, England) · 2012
   Review
5. Development of single-vector Tet-on inducible systems with high sensitivity to doxycycline.Molecular biotechnology · 2012
   Article
6. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.Genome biology · 2007
   Article
7. Introduction of estrogen receptor-alpha into the tTA/TAg conditional mouse model precipitates the development of estrogen-responsive mammary adenocarcinoma.The American journal of pathology · 2003
   Article
8. Interrogating mouse mammary cancer models: insights from gene expression profiling.Journal of mammary gland biology and neoplasia · 2003
   Review
9. Frequent mutations of the Trp53, Hras1 and beta-catenin (Catnb) genes in 1,3-butadiene-induced mammary adenocarcinomas in B6C3F1 mice.Oncogene · 2002
   Article
10. Centrosome abnormalities, recurring deletions of chromosome 4, and genomic amplification of HER2/neu define mouse mammary gland adenocarcinomas induced by mutant HER2/neu.Oncogene · 2002
    Article

Corrections and comments

• Comment on
  The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting.2000
• Comment on
  MMTV-induced mammary tumorigenesis: gene discovery, progression to malignancy and cellular pathways.2000
• Comment on
  Signal transduction in mammary tumorigenesis: a transgenic perspective.2000
• Comment on
  Mutant p53 and genomic instability in a transgenic mouse model of breast cancer.2000
• Comment on
  Dual regulation of proliferation and apoptosis: c-myc in bitransgenic murine mammary tumor models.2000
• Comment on
  The role of prolactin and growth hormone in breast cancer.2000
• Comment on
  Transforming growth factor alpha- and c-myc-induced mammary carcinogenesis in transgenic mice.2000
• Comment on
  Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors.2000

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as